{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T05:24:31Z","timestamp":1762493071078,"version":"build-2065373602"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LMS25H070001"],"award-info":[{"award-number":["LMS25H070001"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2020380946 2022KY172 2024KY1024 2024ZL565"],"award-info":[{"award-number":["2020380946 2022KY172 2024KY1024 2024ZL565"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Primary Aldosteronism (PA), a form of endocrine hypertension (EH), often manifests as Resistant Hypertension (RHTN). RHTN is an increasingly prevalent clinical condition associated with target organ damage and a poor prognosis. Accurate diagnosis and management of EH and PA are challenging due to their diverse clinical manifestations, complex laboratory findings, and potential drug-drug interactions (DDIs). These DDIs, often overlooked in practice, can complicate the diagnostic and treatment processes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Presentation<\/jats:title>\n                    <jats:p>A 56-year-old man with uncontrolled hypertension was admitted to our hospital. He was suspected of having Primary Aldosteronism (PA) and subclinical Cushing\u2019s Syndrome (SCS) based on elevated aldosterone-to-renin ratio (ARR), captopril challenge test results (CCT), and low-dose dexamethasone suppression test (LDDST) results. Adrenal CT showed mild bilateral adrenal hyperplasia. Despite being on six antihypertensive medications, including spironolactone, his blood pressure remained uncontrollable. His medical history revealed prior use of rifampicin for brucellosis. Rifampicin, a CYP450 inducer, caused drug-drug interactions (DDIs), leading to a false-positive dexamethasone suppression test (DST) and reduced efficacy of antihypertensive drugs. After discontinuing rifampicin, his blood pressure was controlled with fewer medications. One month later, repeated ARR and CCT were still positive. Adrenal venous sampling (AVS) indicated bilateral aldosterone secretion without a dominant side, confirming Idiopathic Hyperaldosteronism (IHA). Targeted treatment with MRA led to partial clinical and biochemical remission of PA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case highlights the diagnostic and therapeutic challenges of Endocrine Hypertension (EH) and Primary Aldosteronism complicated by CYP450 enzyme inducers. Specifically, the use of rifampicin, a potent CYP450 inducer, resulted in false-positive diagnostic test results and diminished efficacy of antihypertensive medications, thereby contributing to RHTN. When encountering uncontrolled hypertension, particularly when standard treatments fail, awareness of DDIs is crucial for accurate diagnosis and effective management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1678430","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T05:20:50Z","timestamp":1762492850000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Rifampicin-induced challenges in managing endocrine hypertension and primary aldosteronism: a case report and literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiaoxiao","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minyue","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanxiao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhichao","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Cheok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"B1","first-page":"706","article-title":"Abnormal dexamethasone suppression tests in a rifampicin-treated patient with suspected cushing's syndrome","volume":"61","author":"Abdullah","year":"2010","journal-title":"Endokrynol. Pol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/BF00558219","article-title":"Attenuation of rifampicin-induced theophylline metabolism by diltiazem\/rifampicin coadministration in healthy volunteers","volume":"37","author":"Adebayo","year":"1989","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/s0090-4295(01)01302-4","article-title":"Terazosin, doxazosin, and prazosin: current clinical experience","volume":"58","author":"Akduman","year":"2001","journal-title":"Urology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1002\/ptr.5873","article-title":"Enhanced oral bioavailability of diltiazem by the influence of gallic acid and ellagic acid in Male wistar rats: involvement of CYP3A and P-gp inhibition","volume":"31","author":"Athukuri","year":"2017","journal-title":"Phytother. Res."},{"key":"B47","volume-title":"Revised Aug 2008. Section Clinical Pharmacology","year":"2008"},{"key":"B5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1472-8206.2006.00408.x","article-title":"Characterization of beta-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein","volume":"20","author":"Bachmakov","year":"2006","journal-title":"Fundam. Clin. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/cpt.2141","article-title":"Metamizole is a moderate cytochrome P450 inducer via the constitutive androstane receptor and a weak inhibitor of CYP1A2","volume":"109","author":"Bachmann","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1001\/archinte.144.8.1667","article-title":"Rifampin drug interactions","volume":"144","author":"Baciewicz","year":"1984","journal-title":"Arch. Intern. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1177\/106002808501900712","article-title":"Verapamil-rifampin interaction","volume":"19","author":"Barbarash","year":"1985","journal-title":"Drug Intell. Clin. Pharm."},{"key":"B9","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1111\/bcp.13889","article-title":"Effects of prednisone on docetaxel pharmacokinetics in men with metastatic prostate cancer: a randomized drug-drug interaction study","volume":"85","author":"Belderbos","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.clpt.2006.01.008","article-title":"Female sex and oral contraceptive use accelerate nicotine metabolism","volume":"79","author":"Benowitz","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"B68","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s13318-023-00833-9","article-title":"Management of drug interactions with inducers: onset and disappearance of induction on cytochrome P450 3A4 and uridine diphosphate glucuronosyltransferase 1A1 substrates","volume":"48","author":"Bettonte","year":"2023","journal-title":"Eur. J. Drug Metab. Pharmacokinet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1111\/j.1476-5381.2012.02033.x","article-title":"Differential effects of clinically used derivatives and metabolites of artemisinin in the activation of constitutive androstane receptor isoforms","volume":"167","author":"Burk","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3760\/cma.j.issn.0376-2491.2016.11.002","article-title":"Chinese cushing's disease diagnosis and treatment expert consensus (2015)","volume":"96","year":"2016","journal-title":"Chin. Med. J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.taap.2012.03.008","article-title":"Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux","volume":"260","author":"Crowe","year":"2012","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/hep.20568","article-title":"No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis","volume":"41","author":"Dilger","year":"2005","journal-title":"Hepatology"},{"key":"B15","first-page":"548","article-title":"Changes in cortisol metabolism following rifampicin therapy","volume":"2","author":"Edwards","year":"1974","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/0026-0495(80)90086-4","article-title":"Effects of some clinically encountered drugs on steroid synthesis and degradation","volume":"29","author":"Elias","year":"1980","journal-title":"Metabolism"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1001\/jama.1985.03350310097034","article-title":"Pharmacologic suppression of the fetal adrenal gland in utero. Attempted prevention of abnormal external genital masculinization in suspected congenital adrenal hyperplasia","volume":"253","author":"Evans","year":"1985","journal-title":"JAMA"},{"key":"B18","article-title":"Clinical pharmacology and biopharmaceutics review: telotristat ethyl [EB\/OL]","year":"2017"},{"key":"B19","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/s0090-9556(25)08742-2","article-title":"Spironolactone metabolism in target tissues: characteristics of deacetylation in kidney, liver, adrenal cortex, and testes","volume":"17","author":"Flowers","year":"1989","journal-title":"Drug Metab. Dispos."},{"key":"B20","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.tips.2004.06.002","article-title":"Importance of P-glycoprotein at blood-tissue barriers","volume":"25","author":"Fromm","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s11095-024-03687-1","article-title":"Conversion of olmesartan to Olmesartan Medoxomil, A prodrug that improves intestinal absorption, confers substrate recognition by OATP2B1","volume":"41","author":"Fukazawa","year":"2024","journal-title":"Pharm. Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/cpdd.324","article-title":"Evaluation of pharmacokinetic interactions between lesinurad, a new selective urate reabsorption inhibitor, and CYP enzyme substrates Sildenafil, amlodipine, tolbutamide, and repaglinide","volume":"6","author":"Gillen","year":"2017","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"301","DOI":"10.16439\/j.cnki.1673-7245.2014.04.003","article-title":"How to select antihypertensive drugs for hypertension patients with tuberculosis","volume":"22","author":"Gan","year":"2014","journal-title":"Zhonghua Gao Xue Ya Za Zhi"},{"key":"B24","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0009-9236(03)00187-5","article-title":"The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity","volume":"74","author":"Gorski","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1172\/JCI6663","article-title":"The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin","volume":"104","author":"Greiner","year":"1999","journal-title":"J. Clin. Invest"},{"key":"B26","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00520-006-0127-5","article-title":"The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions","volume":"15","author":"Haddad","year":"2007","journal-title":"Support Care Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1007\/s00204-020-02936-7","article-title":"Inhibition and induction of CYP enzymes in humans: an update","volume":"94","author":"Hakkola","year":"2020","journal-title":"Arch. Toxicol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1507\/endocrj.k10e-402","article-title":"Clinicopathological features of primary aldosteronism associated with subclinical Cushing's syndrome","volume":"58","author":"Hiraishi","year":"2011","journal-title":"Endocr. J."},{"key":"B29","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1021\/js970316d","article-title":"Pharmacokinetics and metabolism of bisoprolol enantiomers in humans","volume":"87","author":"Horikiri","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1586\/ecp.11.30","article-title":"Duration of drug interactions: putative time courses after mechanism-based inhibition or induction of CYPs","volume":"4","author":"Imai","year":"2011","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s00228-009-0707-7","article-title":"CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases","volume":"65","author":"Joy","year":"2009","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1507\/endocrine1927.61.3_145","article-title":"A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy","volume":"61","author":"Kawai","year":"1985","journal-title":"Nihon Naibunpi Gakkai Zasshi"},{"key":"B33","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1365-2125.2006.02733.x","article-title":"Effect of ABCB1 (MDR1) haplotypes derived from G2677T\/C3435T on the pharmacokinetics of amlodipine in healthy subjects","volume":"63","author":"Kim","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B34","first-page":"356","article-title":"Rifampicin interference in the measurement of urinary catecholamines by high-performance liquid chromatography","volume":"45","author":"Kim","year":"2015","journal-title":"Ann. Clin. Lab. Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1097\/00004872-200106001-00004","article-title":"The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction","volume":"19","author":"Laeis","year":"2001","journal-title":"J. Hypertens. Suppl."},{"key":"B36","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1124\/mol.119.116616","article-title":"Mechanistic insights of phenobarbital-mediated activation of human but not mouse Pregnane X receptor","volume":"96","author":"Li","year":"2019","journal-title":"Mol. Pharmacol."},{"key":"B37","first-page":"785","article-title":"The combined effect of isoniazid and rifampicin on the activities of CYP4501A2 and CYP4503A4 in primary hepatocytes from healthy human adults","volume":"28","author":"Liu","year":"2005","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"B38","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/sj.clpt.6100431","article-title":"Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin","volume":"84","author":"Magnusson","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"B39","doi-asserted-by":"publisher","first-page":"605","DOI":"10.2165\/00003088-200140080-00004","article-title":"Drug interactions with irbesartan","volume":"40","author":"Marino","year":"2001","journal-title":"Clin. Pharmacokinet."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/s0090-9556(24)15081-7","article-title":"Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s","volume":"28","author":"McGinnity","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"B41","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/j.1875-9114.1998.tb03830.x","article-title":"Update: clinically significant cytochrome P-450 drug interactions","volume":"18","author":"Michalets","year":"1998","journal-title":"Pharmacotherapy"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.4045\/tidsskr.11.0143","article-title":"Interactions between metoprolol and antidepressants","volume":"131","author":"Molden","year":"2011","journal-title":"Tidsskr. Nor. Laegeforen."},{"key":"B44","doi-asserted-by":"publisher","first-page":"819","DOI":"10.2165\/00003088-200342090-00003","article-title":"Pharmacokinetic interactions with rifampicin: clinical relevance","volume":"42","author":"Niemi","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"B45","doi-asserted-by":"publisher","first-page":"108283","DOI":"10.1016\/j.abb.2020.108283","article-title":"Comparison of steroid hormone hydroxylation mediated by cytochrome P450 3A subfamilies","volume":"682","author":"Niwa","year":"2020","journal-title":"Arch. Biochem. Biophys."},{"key":"B46","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1515\/dmdi.1987.5.4.273","article-title":"The metabolism and biopharmaceutics of spironolactone in man","volume":"5","author":"Overdiek","year":"1987","journal-title":"Rev. Drug Metab. Drug Interact."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2295398","DOI":"10.1080\/07853890.2023.2295398","article-title":"Brucellosis: epidemiology, pathogenesis, diagnosis and treatment-a comprehensive review","volume":"55","author":"Qureshi","year":"2023","journal-title":"Ann. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.tox.2011.03.015","article-title":"Pregnane X receptor mediates the induction of P-glycoprotein by spironolactone in HepG2 cells","volume":"285","author":"Rigalli","year":"2011","journal-title":"Toxicology"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.3390\/pharmaceutics15102486","article-title":"Comprehensive physiologically based pharmacokinetic model to assess drug-drug interactions of phenytoin","volume":"15","author":"Rodriguez-Vera","year":"2023","journal-title":"Pharmaceutics"},{"key":"B51","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40262-024-01350-x","article-title":"Time course of the interaction between oral short-term ritonavir therapy with three factor Xa inhibitors and the activity of CYP2D6, CYP2C19, and CYP3A4 in healthy volunteers","volume":"63","author":"Rohr","year":"2024","journal-title":"Clin. Pharmacokinet."},{"key":"B52","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1177\/0091270003262950","article-title":"Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity","volume":"44","author":"Shadle","year":"2004","journal-title":"J. Clin. Pharmacol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/MNH.0000000000000286","article-title":"Refractory versus resistant hypertension","volume":"26","author":"Siddiqui","year":"2017","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1345\/aph.1P354","article-title":"Induction of CYP3A4 by vinblastine: role of the nuclear receptor NR1I2","volume":"44","author":"Smith","year":"2010","journal-title":"Ann. Pharmacother."},{"key":"B55","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1023\/a:1011902625609","article-title":"Grapefruit juice activates P-glycoprotein-mediated drug transport","volume":"16","author":"Soldner","year":"1999","journal-title":"Pharm. Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3390\/ph18030355","article-title":"Model-Informed dose optimization of spironolactone in neonates and infants","volume":"18","author":"Soliman","year":"2025","journal-title":"Pharm. (Basel)"},{"key":"B57","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/cpt.1918","article-title":"Interpretation of cytochrome P-450 inhibition and induction effects from clinical data: current standards and recommendations for implementation","volume":"109","author":"Stout","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"B58","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4103\/picr.PICR_145_16","article-title":"Study of drug-drug interactions among the hypertensive patients in a tertiary care teaching hospital","volume":"9","author":"Subramanian","year":"2018","journal-title":"Perspect. Clin. Res."},{"key":"B59","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1124\/dmd.108.022707","article-title":"Dehydrogenation of the indoline-containing drug 4-chloro-N-(2-methyl-1-indolinyl)-3-sulfamoylbenzamide (indapamide) by CYP3A4: correlation with in silico predictions","volume":"37","author":"Sun","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"B60","doi-asserted-by":"publisher","first-page":"24248","DOI":"10.1016\/s0021-9258(18)35757-0","article-title":"Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone","volume":"267","author":"Ueda","year":"1992","journal-title":"J. Biol. Chem."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1016\/j.jacc.2013.02.058","article-title":"The P-glycoprotein transport system and cardiovascular drugs","volume":"61","author":"Wessler","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"B62","unstructured":"WHO collaborating centre for drug statistics methodology [EB\/OL]. 2017-06-10\n          \n          \n          2017"},{"key":"B63","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/S0009-9236(98)90163-1","article-title":"Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers","volume":"63","author":"Williamson","year":"1998","journal-title":"Clin. Pharmacol. Ther."},{"key":"B64","doi-asserted-by":"publisher","first-page":"208","DOI":"10.18433\/j3sk5v","article-title":"Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats","volume":"15","author":"Yan","year":"2012","journal-title":"J. Pharm. Pharm. Sci."},{"key":"B65","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S2213-8587(24)00308-5","article-title":"Outcomes after medical treatment for primary aldosteronism: an international consensus and analysis of treatment response in an international cohort","volume":"13","author":"Yang","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3969\/j.issn.1006-5725.2019.01.031","article-title":"A comparative analysis of the antihypertensive effects of rifampicin compared to Nitrendipine and Amlodipine","volume":"35","author":"Ye","year":"2019","journal-title":"J. Pract. Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"692","DOI":"10.3143\/geriatrics.33.692","article-title":"Influence of rifampicin on antihypertensive effects of dihydropiridine calcium-channel blockers in four elderly patients","volume":"33","author":"Yoshimoto","year":"1996","journal-title":"Nihon Ronen Igakkai Zasshi"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1678430\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T05:20:55Z","timestamp":1762492855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1678430\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":67,"alternative-id":["10.3389\/fphar.2025.1678430"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1678430","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"article-number":"1678430"}}